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2In 2011, an estimated 6,300 
Iowans will die from cancer,  
16 times the number caused  
by auto fatalities. Cancer and 
heart disease are the leading 
causes of death in Iowa.  
These projections are based  
upon mortality data the State 
Health Registry of Iowa receives 
from the Iowa Department  
of Public Health. The Registry  
has been recording the occurrence 
of cancer in Iowa since 1973,  
and is one of fourteen  
population-based registries  
and three supplementary  
registries nationwide providing 
data to the National Cancer 
Institute. With 2011 Cancer in 
Iowa the Registry makes a general 
report to the public on the status 
of cancer. This report will focus on:
•	 a	description	of	the	Registry		 	
 and its goals;
•	 cancer	estimates	for	2011;
•	 a	special	section	on		 	 	
 colorectal cancer;
•	 brief	summaries	of	recent/	 	
 ongoing research projects;
•	 a	selected	list	of	publications		 	
 from 2010.
3The State Health Registry of Iowa  
Cancer is a reportable disease as stated in the Iowa Administrative Code.  
Cancer data are collected by the State Health Registry of Iowa, located at The University  
of Iowa in the College of Public Health’s Department of Epidemiology. The staff includes 
more than 50 people. Half of them, situated throughout the state, regularly visit hospitals, 
clinics, and medical laboratories in Iowa and neighboring states to collect cancer data.  
A follow-up program tracks more than 99 percent of the cancer survivors diagnosed since 
1973. This program provides regular updates for follow-up and survival. The Registry 
maintains the confidentiality of the patients, physicians, and hospitals providing data.
In 2011 data will be collected on an estimated 16,500 new cancers among Iowa 
residents. In situ cases of bladder cancer are included in the estimates for bladder cancer, 
to be in agreement with the definition of reportable cases of the Surveillance, Epidemiology, 
and End Results (SEER) Program of the National Cancer Institute.  
Since 1973 the Iowa Registry has been funded by the SEER Program of the National 
Cancer Institute. Iowa represents rural and Midwestern populations and provides data 
included in many National Cancer Institute publications. Beginning in 1990 about 5-10 
percent of the Registry’s annual operating budget has been provided by the state of Iowa. 
Beginning in 2003, the University of Iowa has also been providing cost-sharing funds.  
The Registry also receives funding through grants and contracts with university, state,  
and national researchers investigating cancer-related topics.
The goals of the Registry are to:
•	 assemble	and	report	measurements	of	cancer	incidence,	survival	and	mortality			 	
 among Iowans;
•	 provide	information	on	changes	over	time	in	the	extent	of	disease	at	diagnosis,			 	
 therapy, and patient survival;
•	 promote	and	conduct	studies	designed	to	identify	factors	relating	to	cancer		 	 	
 etiology, prevention and control; 
•	 respond	to	requests	from	individuals	and	organizations	in	the	state	of	Iowa	for		 	 	
 cancer data and analyses; 
•	 provide	data	and	expertise	for	cancer	research	activities	and	educational	opportunities.	
4Cancer Projections for 2011
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Estimated Number of Cancer Deaths in Iowa for 2011
Estimated Number of New Cancers in Iowa for 2011
5New Cancers in Females
Type # of Cancers % of Total
Breast 2160 27.0
Lung 1070 13.4
Colon & Rectum 880 11.0
Uterus 520 6.5
Non-Hodgkin Lymphoma 370 4.6
Skin Melanoma 300 3.8
Thyroid 260 3.2
Ovary 250 3.1
Kidney & Renal Pelvis 230 2.9
Leukemia 210 2.6
All Others 1750 21.9
Total 8000
New Cancers in Males
Type                 # of Cancers % of Total
Prostate 2150 25.3
Lung 1250 14.7
Colon & Rectum 860 10.1
Bladder (invasive and 620 7.3
  noninvasive) 
Non-Hodgkin Lymphoma 420 4.9
Skin Melanoma 420 4.9
Kidney & Renal Pelvis 360 4.2
Leukemia 250 3.0
Oral Cavity 230 2.7
Pancreas 210 2.5
All Others 1730 20.4
Total 8500
Top 10 Types of Cancer in Iowa Estimated for 2011
Cancer Deaths in Females
Type                # of Cancers     % of Total
Lung 800 25.8
Breast 430 13.9
Colon & Rectum 320 10.3
Pancreas 190 6.1
Ovary 180 5.8
Non-Hodgkin Lymphoma 120 3.9
Leukemia 110 3.5
Uterus 100 3.2
Brain 80 2.6
Kidney & Renal Pelvis 70     2.3
All Others 700 22.6
Total 3100
Cancer Deaths in Males
Type                # of Cancers % of Total
Lung 970 30.3
Prostate 330 10.3
Colon & Rectum 300 9.4
Pancreas 180 5.6
Leukemia 150 4.7
Bladder 130 4.1
Esophagus 130 4.1
Non-Hodgkin Lymphoma 130 4.1
Kidney & Renal Pelvis 110 3.4
Brain 100 3.1
All Others 670 20.9
Total 3200
6Between 1973 and 2008, cancer of the colon  
and rectum (colorectal cancer) was the most 
common malignant (invasive) cancer diagnosed 
among Iowans and the second leading cause of 
cancer death. There were 71,880 malignant and 
3,083 in situ (confined to inner layer of wall 
of colon or rectum) colorectal cancers (total= 
74,963) diagnosed during this period affecting 
residents in every county in the state (Figure 1). 
Of these, 95% were diagnosed in Iowans 50 years 
of age and older. The number of colorectal cancers 
has changed during this period from an average of 
1,840 per year in the 1970s, increasing to 2,180 
in the 1980s, peaking at 2,210 in the 1990s, and 
declining to 2,020 in the last decade. The female 
(n=39,049) to male (n=35,914) ratio has been 
1.09 to 1.0.
There were 28,933 deaths due to colorectal 
cancer (CRC) in Iowa for the years 1973-2008 
(Figure 1). The average annual number of deaths 
due to CRC has declined over this period from 
875 per year in the 1970s and 1980s, to 790 
in the 1990s, to 685 in the 2000s. The female 
(n=15,299) to male (n=13,634) ratio for CRC 
deaths has been 1.12 to 1.0.
Another way to assess the burden of CRC is 
to calculate rates. These are a better reflection of 
the disease burden because they account for the 
Figure 1. Newly diagnosed in situ and malignant colorectal cancers and cancer deaths, Iowa, 
1973-2008
Colorectal Cancer
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Brown numbers: newly diagnosed in situ and malignant colorectal cancers
Magenta numbers: colorectal cancer deaths
7Entire state 65.1 (1,840) 71.6 (2,180) 67.4 (2,206) 58.7 (2,024) 18.0%
Gender     
 Male 72.9 (860) 82.7 (1,025) 80.2 (1,070) 67.8 (994) 18.0%
 Female 59.7 (981) 64.1 (1,155) 58.2 (1,136) 51.3 (1,031) 20.0%
     
Age at diagnosis in years     
 0-49 6.8 (99) 6.4 (95) 5.5 (103) 6.6 (134) -3.1%
 50-59 81.4 (249) 86.0 (239) 76.6 (214) 67.4 (250) 21.6%
 60-64 151.5 (198) 178.8 (236) 165.7 (200) 134.0 (175) 25.1%
 65+ 357.8 (1,295) 399.4 (1,610) 384.0 (1,689) 326.7 (1,466) 18.2%
     
Race     
 White 65.1 (1,824) 71.6 (2,157) 67.4 (2,179) 58.6 (1,982) 18.2%
 Black 75.0 (15) 85.6 (21) 74.8 (21) 69.5 (26) 18.8%
 Other 16.8 (1) 19.9 (2) 56.3 (6) 32.0 (9) -61.8%
     
Urban/Rural**	 	 	 	 	
 < 10,000 58.1 (160) 69.1 (197) 68.5 (194) 62.1 (165) 10.1%
 10,000 - 20,000 62.9 (445) 69.0 (517) 67.3 (520) 61.3 (467) 11.2%
 >  20,000 66.9 (463) 73.5 (541) 70.2 (542) 60.7 (481) 17.4%
 MSA# 67.2 (773) 72.8 (926) 65.9 (951) 56.1 (912) 22.9%
     
*	Rates	are	per	100,000	population,	include	in	situ	and	malignant,	and	age-adjusted	to	the	2000	US	standard	population	 	
**	Urban/rural	county	average	population	groupings	were	obtained	from	the	2009	Iowa	Health	Fact	Book	 
(see	http://www.public-health.uiowa.edu/factbook/)	 	 	 	 	
# Metropolitan statistical area (MSA) consists of one or more counties that contain a city of 50,000 or more residents  
   
Table 1. In situ and malignant colorectal cancer incidence rates* (average annual number  
of cancers) by time period and selected characteristics, Iowa, 1973-2008    
 
 
African Americans have higher colorectal  
cancer incidence and mortality rates than  
whites or other races in Iowa and in the  
United States.
population at risk. Table 1 shows that new cases  
of in situ and malignant CRC (incidence) rates have 
declined over the past two decades for both males 
and females, those 50 years of age and older, white 
and black racial groups, and groupings of Iowa 
counties from the most rural to the most urban. 
Comparing the 1980 decade with the most recent 
decade, the statewide incidence rates have declined 
18%. This level of decline has been seen in every 
group	shown	in	Table	1	except	those	diagnosed	
under age 50 years, people living in non-MSA 
counties, and Iowans of racial groups other than 
white or black where the average annual number  
of new cancers is small and the rates unstable.       
Characteristic                  Time Period                              % Reduction     
   1973-1979      1980-1989         1990-1999         2000-2008     1980s vs. 2000s  
Brown numbers: newly diagnosed in situ and malignant colorectal cancers
Magenta numbers: colorectal cancer deaths
8Table 2 shows that death (mortality) rates due 
to CRC have been similar to the incidence rate 
findings. Comparing the 1980 decade with the 
most recent decade, the statewide mortality rates 
have declined over 30%. This level of decline has 
been	seen	in	every	group	shown	in	Table	2	except	
people living in counties with average populations 
< 20,000, and Iowans of racial groups other than 
white or black where the average annual number 
of CRC deaths is small and the rates unstable.       
Iowa is making progress in decreasing the health burden of colorectal cancer. 
Screening or early detection and treatment  
is a key way to reduce incidence and death from 
CRC. Incidence can be reduced through the 
removal of polyps, which are premalignant lesions. 
Staging is performed by health care providers  
to determine how far a cancer has spread.  
Early stage colorectal cancers are confined to  
the wall of the colon or rectum and can be  
treated by surgical removal resulting in a cure 
from this disease. In late stage CRC the disease 
Table 2. Colorectal cancer mortality rates* (average annual number of deaths) by time  
period and selected characteristics, Iowa, 1973-2008        
 
Characteristic              Time Period                              % Reduction    
  1973-1979    1980-1989     1990-1999      2000-2008       1980s vs. 2000s  
  
Entire state 31.0 (873) 28.5 (874) 23.7 (792) 19.1 (684) 33.0%  
  
Gender        
 
 Male 36.1 (412) 33.0 (401) 29.0 (378) 22.7 (329) 31.2%  
  
 Female 27.8 (461) 25.5 (473) 20.2 (414) 16.3 (356) 36.1%  
           
Age at diagnosis in years        
 
 0-49 2.7 (39) 2.2 (32) 1.4 (27) 1.3 (26) 40.9%  
  
 50-59 31.8 (97) 29.5 (82) 22.3 (62) 16.9 (63) 42.7%  
  
 60-64 62.6 (82) 62.0 (82) 51.9 (63) 37.2 (49) 40.0%  
  
 65+ 182.9 (655) 168.3 (678) 143.9 (641) 117.3 (547) 30.3%  
           
Race        
 
 White 31.1 (866) 28.5 (865) 23.6 (781) 19.1 (673) 33.0%  
  
 Black 30.7 (6) 37.2 (9) 31.0 (8) 26.6 (9) 28.5%  
  
 Other 3.0 (0.1) 7.0 (0.6) 23.2 (2) 9.7 (2) -38.6%  
           
Urban/Rural**	 	 	 	 	 	 	 	
 
 < 10,000 31.5 (87) 28.8 (84) 24.9 (74) 20.8 (59) 27.8%  
  
 10,000 - 20,000 28.8 (204) 28.2 (215) 24.0 (192) 20.4 (166) 27.7%  
  
 >  20,000 32.2 (221) 28.3 (211) 24.6 (194) 19.4 (160) 31.4%  
  
 MSA# 31.7 (360) 28.8 (364) 22.9 (333) 18.1 (299) 37.2%  
  
         
*	Rates	are	per	100,000	population	and	age-adjusted	to	the	2000	US	standard	population	 	 	 	 	 	
	**	Urban/rural	county	average	population	groupings	were	obtained	from	the	2009	Iowa	Health	Fact	Book	 
(see	http://www.public-health.uiowa.edu/factbook/)	 	 	 	 	 	 	 	 	
# Metropolitan statistical area (MSA) consists of one or more counties that contain a city of 50,000 or more residents   
      
9Health has been tracking use of these screening 
options among the Iowa population for several 
years. Between 1999 and 2008, the percent 
of the Iowa population reporting ever having 
had a sigmoidoscopy or colonoscopy increased 
substantially in males and females and by age 
as presented in Figure 3a. During this same time 
period, the use of the blood stool test decreased  
in each of these categories (Figure 3b). 
Risk factors for CRC other than age and race 
include a personal history of CRC, polyps, or 
chronic inflammatory bowel disease; a family 
history of CRC or polyps in one or more first-degree 
relatives (a parent, brother, sister, son or daughter); 
or a family history of a hereditary CRC syndrome. 
Screening should be considered earlier than  
age 50 for people with any of these risk factors.  
In addition, lifestyle factors can increase the risk 
of CRC. These factors include diets high in fat and 
calories and low in fiber, physical inactivity, obesity, 
smoking, heavy alcohol use, and type 2 diabetes.  
Screening can explain the declining colorectal 
incidence and mortality rates being observed 
in Iowa. However, there are still significant 
numbers of Iowans who have not been 
screened at recommended intervals.   
has spread beyond the wall or to nearby lymph 
nodes (regional stage) or has spread to more 
distant sites (distant stage). Early stage CRC is 
associated with an increasing likelihood of survival 
(Figure 2). For Iowans diagnosed with CRC  
between 1973 and 2007, 14,300 are still alive 
today. The number of survivors will increase if  
the disease is detected earlier.
Research has shown that screening is effective 
in preventing the development of CRC or detecting 
invasive disease earlier in its course. CRC begins 
with small growths called adenomatous polyps.  
As these polyps grow, they may become cancerous. 
The United States Preventive Services Task Force,  
a group of individuals who review evidence about 
the effectiveness of screening, recommends 
screening for CRC in adults at average risk between 
ages 50 and 75 years by any of the following  
tests: 1) annual sensitive fecal occult blood tests, 
2)	flexible	sigmoidoscopy	every	5	years	combined	
with high-sensitivity fecal occult blood testing every 
3 years, and 3) screening colonoscopy at intervals 
of 10 years. Each of these three regimens has 
been	shown	to	be	equally	effective	in	terms	of	
prolonging life, assuming perfect adherence to  
the regimen. Thus, adherence to the recommended 
frequency	of	testing	is	more	important	than	
the specific test chosen. If a test is positive or 
abnormal, a colonoscopy will be done to make 
sure that there are no premalignant polyps or if 
there are, that these are removed. The United 
States Preventive Services Task Force recommends 
discontinuing screening at age 75, unless there  
are individual reasons to do so. Newer tests for 
CRC screening are coming out. To date, other  
tests for screening such as the fecal DNA test  
and	computerized	tomographic	colonography	  
(CTC) have not been shown to reduce deaths  
from CRC. You should talk with your doctor  
if	you	have	questions	about	specific	tests.
For screening options, most Iowans have been 
choosing	the	stool	blood	test	or	sigmoidoscopy/
colonoscopy. The Iowa Department of Public 
Figure 2. Colorectal Cancer 5-year Relative Survival  
by Stage, Iowa, Diagnosed 2001-2002
10
The Iowa Department of Public Health funded a 
health	care	provider	education/persuasion	campaign	
to help primary care providers in Iowa talk to their 
patients about the importance of CRC screening. 
The ICC is a collaboration of individuals and 
organizations	from	across	Iowa,	and	would	not	be	
able to implement its plan or mission without the 
active involvement of its members. You can join this 
effort. For more information contact the ICC: 
Phone: 1-800-237-1225 or 319-335-8144
Email: info@canceriowa.org
Internet: www.CancerIowa.org   
      
Colorectal Cancer
Figure 3b. Percent of Iowa Population Who had  
a Blood Stool Test within the Past Two Years by  
Age Group and Gender
Figure 3a. Percent of Iowa Population Who have  
Ever had a Sigmoidoscopy or Colonoscopy by  
Age Group and Gender
Despite the benefits and availability of screening, 
there remain substantial portions of Iowans who 
have	never	had	any	screening	exam	for	CRC.	The	
Iowa Cancer Consortium (ICC) coordinates the 
collaborative efforts of hundreds of individuals and 
organizations	who	work	together	to	conquer	cancer.	
The	ICC	and	its	member	organizations	are	active	
in providing CRC screening education, reducing 
barriers to CRC screening, enrolling CRC patients 
into clinical trials to treat this disease with the 
most	appropriate	therapy,	assuring	that	the	quality	
of life for every CRC survivor is the best it can 
be, and conducting research to further reduce the 
incidence and mortality rates for CRC and move 
these research findings into prevention, treatment, 
and control practices.    
A	few	examples	of	specific	activities	led	by	
the	University	of	Iowa,	the	ICC,	and/or	the	Iowa	
Department of Public Health are as follows:  
Researchers for a currently funded grant at  
the University of Iowa are seeking input from 
Iowans about how best to promote CRC screening, 
since this is a curable cancer if detected early. 
The grant funds five Community Assistants who 
will hold “town hall” type meetings with their 
constituents across Iowa to find out how to get 
information out on CRC screening. 
The ICC collaborated with the Iowa Foundation 
for Medical Care and the American Cancer Society 
to provide several hundred stool blood test kits 
along with educational materials to Iowans over 50 
year of age to increase screening rates. In addition, 
health providers received fact sheets on how to talk 
to patients about CRC screening options. 
The ICC provides an annually updated map at 
www.canceriowa.org/Iowa-Get-Screened-Map.aspx/ 
that identifies free and reduced-cost CRC screening 
locations. The Iowa Department of Public Health 
created and distributed three separate CRC screening 
campaigns in the past few years directed at rural 
Iowans, African Americans, and a campaign in 
Spanish	targeted	toward	the	Latino/Hispanic	
community. 
Source:	http://apps.nccd.cdc.gov/brfss/
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Research Projects During 2011
The State Health Registry of Iowa is participating 
in	over	three	dozen	funded	studies	during	2011.	
Brief descriptions of a few of these studies are 
provided.
AGRICULTURAL HEALTH STUDY
The Agricultural Health Study is a long-term study 
of	agricultural	exposures	(including	pesticides)	
and chronic disease (especially cancer) among 
commercial or private pesticide applicators (and 
their spouses, if married) in Iowa and North 
Carolina. The study is funded through the National 
Cancer Institute and involves several federal 
agencies. We are in the 19th year of the study. 
In the first five years, 89,658 subjects (58,564 
in Iowa and 31,094 in North Carolina) were 
enrolled in the study. This total for Iowa included 
31,877 private applicators, 21,771 spouses of 
private applicators, and 4,916 commercial 
applicators. Enrollment consisted of completing 
questionnaires	about	past	exposures	and	health.	
The second phase of the study for private 
applicators and their spouses was completed  
at the end of 2003. It involved a telephone 
interview,	a	mailed	dietary	questionnaire,	and	
collection of a cheek cell sample from all 
consenting cohort members. The telephone 
interview asked about pesticide use since 
enrollment, current farming and work practices,  
and health changes. The dietary health 
questionnaire	asked	about	cooking	practices	  
and types of foods eaten. Cooking practices and 
diet may play a role in cancer and other health 
conditions. The cheek cells are being used to 
understand possible links between genetics, 
exposures,	and	disease.	For	commercial	
applicators, the second phase of the study was 
completed at the end of 2005. The study’s third 
phase began in 2005 and ended in 2010.  
It	 involved	updating	 information	about	exposures	
and health. Plans for a fourth phase of the study 
are being developed.   
Since 1997, cohort members have been linked 
annually to mortality and cancer registry incidence 
databases in both states. In addition, mortality  
data on the cohort are being obtained from the 
National	Death	Index.	More	 information	about	  
results from this study, the study background, 
frequently	asked	questions,	other	resources	  
(internet & telephone) for agricultural health 
information, references for publications to date,  
and information for scientific collaborators can be 
found at the website, www.aghealth.org. The titles  
for over 100 publications from this study linked  
to PubMed are available at the website. The cancer-
related references for 2010 publications are provided 
in the last section of this report. 
    
GEOGRAPHIC INFORMATION SYSTEMS
The State Health Registry of Iowa is involved with 
research	utilizing	geographic	 information	systems	  
to develop and test methodologies to identify 
regions	of	excess	cancer	burden	in	Iowa.	Geographic	
information systems are refining measures of 
geographic access to cancer prevention, treatment 
and screening services in Iowa by using fine-scaled 
geographic data on individuals, the spatial choices 
of individuals, and the locations of service providers. 
Results can be used to plan more appropriate cancer 
prevention and control programs. 
The Registry has been mostly involved with this 
for the four major cancers in Iowa. One activity has 
been to create maps for use by the Iowa Cancer 
Consortium to assist with planning for cancer 
prevention and control. These maps were created 
under the direction of Dr. Gerard Rushton,  
Professor of Geography at the University of Iowa, 
and	his	graduate	students.	Examples	can	be	viewed	
at http://www.canceriowa.org/News---Publications/
GIS-Smoothed-Cancer-Maps-of-Iowa.aspx.  
The references for a couple of recent publications 
involving geographic information systems are  
provided in the last section of this report. 
    
IOWA WOMEN’S HEALTH STUDY
This is a population-based cohort of 41,837 Iowa 
women, aged 55-69 in 1986, who were recruited 
to determine whether diet, body fat distribution and 
Figure 3b. Percent of Iowa Population Who had  
a Blood Stool Test within the Past Two Years by  
Age Group and Gender
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other risk factors were related to cancer incidence. 
Exposure	and	lifestyle	 information	was	collected	
in	a	baseline	mailed	survey	and	subsequently	in	
several follow-up mailed surveys. Mortality and 
cancer incidence have been ascertained since 
1986 through annual linkage to the State Health 
Registry of Iowa databases and the National Death 
Index.	In	2010	the	study	was	refunded	for	its	
25th through 29th years. The project has been 
extremely	productive	with	over	200	publications,	
some of which occurred in 2010 and are listed  
in the references provided in the last section of 
this report. 
NON-HODGKIN LYMPHOMA (NHL)  
CASE-CONTROL STUDY
The State Health Registry of Iowa with other 
investigators at the Mayo Clinic participated in a 
collaborative, population-based case-control study 
of NHL involving researchers at the National 
Cancer Institute and three other Surveillance, 
Epidemiology, and End Results (SEER) registries. 
The main objective of the study was to better 
characterize	risk	factors	for	NHL.	In	Iowa,	364	
live patients newly diagnosed with NHL between 
July 1, 1998 and June 30, 2000 were enrolled.  
A similar number of population controls 
participated. Blood samples were sought from 
study participants. The State Health Registry of 
Iowa	also	coordinated	the	acquisition	of	pathology	
reports, slides and tissue blocks from all SEER 
centers. The slides were reviewed to determine  
the reliability of NHL pathologic classification. 
More recently, we are collaborating with 
researchers at the Mayo Clinic to investigate 
whether genes with functional, common variant 
polymorphisms involved in immune function and 
regulation are associated with overall survival 
from NHL among these patients. To achieve this 
aim, medical record reviews were performed to 
obtain more detailed information on the treatment 
received for NHL. These research activities 
resulted in several publications during 2010.  
The references for these are provided in the  
last section of this report. 
PATTERNS OF CARE STUDIES
SEER Patterns of Care Studies are conducted 
to satisfy a U.S. Congressional directive to 
the National Cancer Institute to “assess the 
incorporation of state-of-the-art cancer treatment 
into	clinical	practice	and	the	extent	to	which	
cancer patients receive such treatments and 
include the results in such assessment in the 
biennial reports.” This year’s Patterns of Care 
Study will involve urinary bladder, head and neck, 
pancreas, and kidney cancers in adults diagnosed 
between January 1, 2009 and December 31, 
2009. The objectives of the SEER Patterns of 
Care Study are to: 1) describe the use of adjuvant 
therapy, which has been verified with the treating 
physician,	 in	a	community	setting,	2)	characterize	
the practice patterns in different communities,  
3) describe more completely the use of  
surgery in the treatment of specific cancers,  
4) compare the patterns of treatment for cancer 
over time, 5) compare patterns of care by age 
and	race/ethnicity,	6)	describe	effect	of	  
co-morbid conditions on treatment, and  
7) describe treatment by hospital characteristics: 
i.e. for profit vs. not for profit, teaching vs.  
non-teaching, disproportionate share status, etc. 
The SHRI has been involved with these types  
of studies over the past 20 years. During 2010,  
they have resulted in a few publications, which 
are provided in the last section of this report. 
POOLED ANALYSES
Today, researchers are increasingly looking to 
combine their study data with data from other 
studies evaluating similar outcomes. Several 
studies that involve the State Health Registry 
of Iowa have had their data contributed for this 
pooling research including the Agricultural Health 
Study, the Iowa Women’s Health Study, the NHL 
Case-Control Study, and the American Cancer 
Society’s Cancer Prevention Study II Nutrition 
Cohort. During 2010, these activities addressed 
cancer risk associated with common lifestyle  
and/or	genetic	susceptibility	factors	and	resulted	
in several publications.
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TRANSPLANT CANCER MATCH STUDY
Solid organ transplantation provides life-saving 
treatment for end-stage organ disease but is 
associated with substantially elevated cancer risk, 
largely due to the need to maintain long-term 
immunosuppression.	Important	questions	remain	
concerning the role of immunosuppression and 
other factors in causing cancer in this setting. 
Staff at two federal agencies, the National Cancer 
Institute and the Health Resources and Services 
Administration, are creating a database through 
linkage of information on U.S. transplant  
recipients (383,444 transplant recipients during 
1987-2007), wait list candidates (216,067 
candidates during 1987-2007 in addition to those 
who	were	subsequently	transplanted),	and	donors	
(61,430 deceased donors, 57,961 living donors 
during 1999-2007) with information on cancer 
from multiple U.S. cancer registries, including  
the State Health Registry of Iowa. These data  
are being used to conduct research concerning  
the spectrum of cancer risk in transplant recipients. 
The data will also be used by the Health Resources 
and Services Administration in its public health 
role overseeing the U.S. solid organ transplant 
network to maintain and improve safety of organ 
transplantation, and will allow the National Cancer 
Institute	to	better	characterize	the	burden	of	  
cancer in this population and discover risk factors 
for cancer among immunosuppressed individuals.
WECARE STUDY  
The WECARE (Women’s Environmental Cancer 
and	Radiation	Epidemiology)	Study	 is	an	example	
of a second cancer study. This study is designed 
to	examine	gene	carrier	status,	demographic	and	
lifestyle factors as well as environmental and 
treatment factors reported to be associated with 
breast cancer as they relate to the development 
of a second breast cancer in the opposite breast. 
Data collection not only involved medical record 
review, but also participant interviews and blood  
or buccal (cells from the mouth) sample collection. 
This year, we are back in the field adding more 
participants to this study to enable a genome-wide 
association study to be conducted to learn more 
about how genetic, environmental, and lifestyle 
factors work together to influence whether a woman 
with breast cancer will develop a second breast 
cancer in the opposite breast.       
Results from the WECARE Study have provided 
important medical information and will continue  
to do so in the future. During 2010, findings from  
this	study	resulted	in	a	half-dozen	publications,	  
the references for which are provided in the last 
section of this report. 
SEER-MEDICARE
In the early 1990s, the cancer incidence and 
survival data from the State Health Registry of 
Iowa was combined with other SEER Registry data 
and linked to Medicare data. This linked data set 
has been updated on several occasions since and 
has become an important data resource for cancer 
research involving epidemiologic and health services 
research related to the diagnosis, treatment and 
procedures, costs, and survival of cancer patients. 
Over the years many publications have resulted from 
this linked data set including several during 2010, 
which	are	 listed	at	http://healthservices.cancer.gov/
seermedicare/overview/publications.html.	 	
COOPERATIVE AGREEMENTS AND  
OTHER REGISTRIES
The State Health Registry of Iowa maintains 
cooperative agreements with several hospital cancer 
registries	and	other	agencies/entities.	Some	of	the	
latter include:
•	 Iowa	Department	of	Public	Health
•	 Iowa	Cancer	Consortium	
•	 The	University	of	Iowa
  - Center for Health Effects of Environmental   
  Contamination
  -  Center for Public Health Statistics
  -  Environmental Health Sciences  
  Research Center
  -  Health Effectiveness Research Center
  -  Holden Comprehensive Cancer Center
  -  Iowa Center for Agricultural Safety and Health
  -  Injury Prevention Research Center
  -  Preventive Intervention Center 
  -  Reproductive Molecular Epidemiology    
  Research & Education Program
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